Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial

Systemic treatments are limited for patients with meningiomas that have progressed after surgery or radiation. Loss of NF2 and CDKN2A/CDKN2B is common in higher-grade meningiomas and promotes progression in preclinical models. We evaluated the efficacy of abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, as one arm of the Alliance umbrella trial A071401, a genomically driven phase 2 study in recurrent and progressive meningiomas. Eligible patients with grade 2 or 3 tumors and NF2 mutations or CDK pathway alterations were treated with abemaciclib. Two co-primary endpoints were used: progression-free survival at 6 months (PFS6) and response rate as defined by local review; the trial would be declared positive if either endpoint was met. The success threshold for PFS6 was 8 or more of 24 patients; for the response rate, it was 3 or more of 24 patients. Ninety-six patients were screened and 36 patients received treatment. The mean number of treatment cycles was nine and the median follow-up was 21 months. The first 24 patients who met the eligibility criteria and began treatment could be evaluated for the primary endpoint. The observed PFS6 rate was 58% (14 of 24 patients, 95% confidence interval = 37-78%), thus meeting the PFS6 criteria for promising activity. The best response was stable disease in 16 of 24 patients. Of the 36 patients who started treatment, nine had a grade 3 and two had grade 4 adverse events at least possibly related to treatment. Grade 4 toxicities included alanine aminotransferase elevation (1), aspartate aminotransferase elevation (1) and vomiting (1). The trial met its primary endpoint. Abemaciclib was well tolerated and resulted in improved PFS6. Abemaciclib warrants further investigation for patients with progressive grade 2 or 3 meningiomas harboring NF2 or CDK pathway alterations. ClinicalTrials.gov registration no. NCT02523014 .

Authors

Institutions

Publication Details

Journal
Nature Medicine
Published
2026-01-16
DOI
https://doi.org/10.1038/s41591-025-04141-4
Primary Topic
Meningioma and schwannoma management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial

Nawal Shaikh, Lindsay Robell, Sandro Santagata, Daniel P. Cahill et al.
Nature Medicine
Meningioma and schwannoma management
article

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial

Nawal Shaikh, Lindsay Robell, Sandro Santagata, Daniel P. Cahill, Mary Welch, Evanthia Galanis, Roy E. Strowd, Adam L. Cohen, Thomas Kaley, Stefan T. Kaluziak, Katharine Dooley, Amy Chan, David Piccioni, Ian Rabinowitz, Mohammed Milhem, Joo Yeon Nam, Elizabeth R. Gerstner, Elizabeth Codd, Kurt Jaeckle, Alissa A. Thomas, Rajiv S. Magge, Timothy J. Kaufmann, Carlos Kamiya Matsuoka, Maria Martinez-Lage, A. John Iafrate, Frederick G. Barker, Jan Drappatz, Priscilla K. Brastianos, Nicholas Blondin, Susan Geyer, Paul Brown
article en

Abstract

Systemic treatments are limited for patients with meningiomas that have progressed after surgery or radiation. Loss of NF2 and CDKN2A/CDKN2B is common in higher-grade meningiomas and promotes progression in preclinical models. We evaluated the efficacy of abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, as one arm of the Alliance umbrella trial A071401, a genomically driven phase 2 study in recurrent and progressive meningiomas. Eligible patients with grade 2 or 3 tumors and NF2 mutations or CDK pathway alterations were treated with abemaciclib. Two co-primary endpoints were used: progression-free survival at 6 months (PFS6) and response rate as defined by local review; the trial would be declared positive if either endpoint was met. The success threshold for PFS6 was 8 or more of 24 patients; for the response rate, it was 3 or more of 24 patients. Ninety-six patients were screened and 36 patients received treatment. The mean number of treatment cycles was nine and the median follow-up was 21 months. The first 24 patients who met the eligibility criteria and began treatment could be evaluated for the primary endpoint. The observed PFS6 rate was 58% (14 of 24 patients, 95% confidence interval = 37-78%), thus meeting the PFS6 criteria for promising activity. The best response was stable disease in 16 of 24 patients. Of the 36 patients who started treatment, nine had a grade 3 and two had grade 4 adverse events at least possibly related to treatment. Grade 4 toxicities included alanine aminotransferase elevation (1), aspartate aminotransferase elevation (1) and vomiting (1). The trial met its primary endpoint. Abemaciclib was well tolerated and resulted in improved PFS6. Abemaciclib warrants further investigation for patients with progressive grade 2 or 3 meningiomas harboring NF2 or CDK pathway alterations. ClinicalTrials.gov registration no. NCT02523014 .

Nature MedicineVol. 32(2)
University of Iowa (US), Rush University Medical Center (US), Dartmouth–Hitchcock Medical Center (US), Mayo Clinic (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), University of New Mexico (US), Cornell University (US), University of Michigan (US), Columbia University Irving Medical Center (US), UC San Diego Health System (US), Jacksonville College (US), University of Vermont Medical Center (US), Jackson Memorial Hospital (US), University of Mississippi Medical Center (US), University of Chicago (US), Massachusetts General Hospital (US), Virginia Cancer Institute (US), Dana-Farber Cancer Institute (US), Mayo Clinic in Arizona (US), UPMC Hillman Cancer Center (US), Dana-Farber/Harvard Cancer Center (US), New Mexico Cancer Center (US), Mayo Clinic in Florida (US), Smilow Cancer Hospital (US), UNM Comprehensive Cancer Center, University of Iowa Holden Comprehensive Cancer Center, Wake Forest University (US)
Good health and well-being
Openalex Percentile: Top 86%
Meningioma and schwannoma management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.